Association between overt, subclinical hypothyroidism and metabolic dysfunction-associated steatotic liver disease using magnetic resonance imaging

Table 8 Comparing demographic and laboratory characteristics among the mild and moderate metabolic dysfunction-associated steatotic liver disease groups, mean ± SD

Variable	Mild MASLD	Moderate MASLD	P value
Age (years)	36 ± 9	36 ± 9	0.940
BMI (kg/m2)	31 ± 2	31.7 ± 2.3	0.238
Duration of hypothyroidism (years)	4.2 ± 1.6	4.3 ± 2	0.821
ALT (U/L)	19.2 ± 8.1	42.1 ± 79.6	0.106
AST (U/L)	20.5 ± 5.3	34.2 ± 41.4	0.065
TSH (mIU/L)	13.8 ± 16.1	32.6 ± 31.5	0.005
FT4 (ng/dL)	1 ± 0.2	0.9 ± 0.4	0.039
Total cholesterol (mg/dL)	186.2 ± 32.4	197.7 ± 47	0.253
High density lipoprotein (mg/dL)	48.8 ± 10.4	48.5 ± 13	0.919
Low density lipoprotein (mg/dL)	114.2 ± 25.8	122.6 ± 37.7	0.299
HF (%)	15.9 ± 7.8	30.8 ± 3.5	< 0.001
Triglycerides (mg/dL), median (range)	105 (39-322)	107 (33-356)	0.777
Fib4 score, median (range)	0.3 (0.1-0.8)	0.3 (0.1-0.7)	0.438

P value < 0.05 is considered significant. MASLD: Moderate metabolic dysfunction-associated steatotic liver disease; BMI: Body mass index; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TSH: Thyroid-stimulating hormone; FT4: Free thyroxine; HF: Hepatic fat; Fib4: Fibrosis-4 index.